Skip to content

DNA methylation analysis on self-samples for cervical cancer detection

Validation of DNA methylation analysis on self-collected vaginal specimens collected with Floqswab for cervical cancer detection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN51391184
Enrollment
140
Registered
2026-04-20
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical (pre)cancer Cancer

Interventions

At least 70 high-risk HPV+ women with CIN3+ and 70 high-risk HPV+ women without evidence of disease (or at maximum CIN1
i.e. =CIN1) are required (n = 140 in total). HPV detection is not routinely performed at Tashkent. Therefore the colposcopic impression of women will be used to determine if women are eligible for stu

Sponsors

Self-screen B.V.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All women aged 25 years or older attending the Waylon women’s health clinic for their routine colposcopic examination of the cervix 2. Women with a colposcopic impression of CIN3+ 3. Women with a colposcopic impression that is normal or CIN1 4. Women who consented to participate in the study

Exclusion criteria

Exclusion criteria: 1. Women with insufficient sample volume of clinician-taken and/or self-collected specimen for testing for high-risk HPV and methylation 2. Women who test high-risk HPV negative on their clinician-taken sample 3. Women who objected to the use of their personal data and/or sample material before, during or after the study

Countries

Uzbekistan

Contacts

Public ContactMukhabbat Ahkmedova
wwc-akhmedova@mail.ru+998 (0)908088011

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026